MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/650/0.01/20.12.24 | Real-time Bid/Ask 11:24:03 2024-05-30 EDT | ||
| 0.068 EUR / 0.078 EUR | +7.35% |
|
| Current month | +15.25% | ||
| 1 month | +15.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-30 | 0.068 | 0.00% |
| 24-05-29 | 0.068 | -5.56% |
| 24-05-28 | 0.072 | +4.35% |
| 24-05-27 | 0.069 | -1.43% |
| 24-05-24 | 0.07 | +1.45% |
Delayed Quote Börse Stuttgart
Last update May 30, 2024 at 09:13 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME6ZWJ |
| ISIN | DE000ME6ZWJ8 |
| Date issued | 2024-01-16 |
| Strike | 650 $ |
| Maturity | 2024-12-20 (204 Days) |
| Parity | 100 : 1 |
| Emission price | 0.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.115 € |
|---|---|
| Lowest since issue | 0.05 € |
| Spread | 0.01 € |
| Spread % | 12.66% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
441.1
USD
Average target price
462.8
USD
Spread / Average Target
+4.92%
- Stock Market
- Warrants
- Warrant
